A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers-Reference-Cited by-同舟云学术

A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers

Published:2012-04 Issue:14 Volume:59 Page:1304-1311
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Frelinger Andrew L.,Lee Ronald D.,Mulford Darcy J.,Wu Jingtao,Nudurupati Sai,Nigam Anu,Brooks Julie K.,Bhatt Deepak L.,Michelson Alan D.

Funder

Takeda Global Research & Development Center

Arena Pharmaceuticals

GLSynthesis

Eli Lilly/Daiichi Sankyo

Sanofi Aventis/Bristol-Myers Squibb

Amarin

AstraZeneca

Bristol-Myers Squibb

Eisai

Ethicon

Medtronic

Sanofi Aventis

The Medicines Company

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

2. Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin;Karol;J Clin Pharmacol,1999

3. Influence of lansoprazole treatment on diazepam plasma concentrations;Lefebvre;Clin Pharmacol Ther,1992

4. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies;Vakily;Clin Drug Invest,2009

5. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate;Bonello;J Am Coll Cardiol,2010

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

2. An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?;Expert Opinion on Drug Metabolism & Toxicology;2024-07-15

3. Investigation into the impact of proton pump inhibitors on sertraline transport across the blood-brain barrier;European Journal of Pharmaceutical Sciences;2024-03

4. Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases;Toxicology and Applied Pharmacology;2023-09

5. Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis;European Heart Journal;2023-07-13